Bristol Myers Squibb (CELG-RI) Long-Term Investments (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Long-Term Investments for 17 consecutive years, with $397.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Long-Term Investments rose 14.74% year-over-year to $397.0 million; the TTM figure through Jun 2026 stood at $397.0 million (up 14.74% YoY), while the FY2025 annual figure was $396.0 million, up 23.75% from the prior year.
• Long-Term Investments rose to $397.0 million in Q2 2026 per CELG-RI's latest filing, from $366.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $406.0 million in Q3 2025 and bottomed at $320.0 million in Q4 2024.
• Historically, Long-Term Investments has averaged $362.5 million across 4 years, with a median of $364.0 million in 2023.
• Annual changes were most pronounced in 2024 — Long-Term Investments decreased 12.09% — and 2025, when it increased 25.31%.
• Bristol Myers Squibb's Long-Term Investments stood at $364.0 million in 2023, then decreased by 12.09% to $320.0 million in 2024, then gained by 23.75% to $396.0 million in 2025, then grew by 0.25% to $397.0 million in 2026.
• Business Quant data shows CELG-RI's Long-Term Investments at $397.0 million in Q2 2026, $366.0 million in Q1 2026, and $396.0 million in Q4 2025.